Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

3 Genius Quantum Computing Stocks to Buy Now

Key PointsIonQ is the upstart of this bunch -- offering investors a pure-play quantum computing pick.

Quantum computing is advancing faster than many investors anticipate, with some predicting a 2029 breakthrough. To capitalize on this, a diversified portfolio of quantum computing stocks is recommended. The proposed basket includes IonQ (IONQ), Alphabet (GOOG) and GOOGL, and Nvidia (NVDA), each representing varying degrees of risk and investment.

IonQ, identified as the most aggressive option, is committed to delivering viable quantum computing solutions. Its upcoming 256-qubit system could serve as a significant milestone for early-stage integration, though its success remains uncertain. Alphabet, displaying moderate aggressiveness, is quietly pursuing quantum computing development, with its Willow quantum computing chip at the forefront.

This could potentially revolutionize Google Cloud, but Alphabet's secretive approach contrasts with IonQ's more outspoken stance.

Nvidia, the most conservative pick, focuses on traditional accelerated computing units, with a strategic plan to integrate quantum computing where necessary. By leveraging its NVQLink and CUDA software, Nvidia aims to ensure its dominance in both traditional and hybrid computing environments. Despite the uncertainty surrounding quantum computing, Nvidia's broad range of applications, particularly in AI, positions it as a promising tech investment for the foreseeable future.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

Auction market collapses to record low

Over the years, weekend property auction results have become a key barometer the media uses to illustrate the housing market’s strength at a given moment.

  • Sydney auction market crashes to record low
  • Only 24.6% of properties sold, down from 27.1% a fortnight ago
  • SQM Managing Director warns of troubled market

Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?

Bristol Myers Squibb is facing a sizable patent cliff, but that's not unusual in the pharma sector.

  • Bristol Myers Squibb trades at 9.7 times forward earnings, below the five-year average
  • Competitor Eli Lilly has a much higher forward earnings ratio of 35.6 times
  • Bristol Myers Squibb's lower valuation stems from upcoming patent expirations on Opdivo and Eliquis

More from Sunday 25 October →